HORIZON-MISS-2027-02-CANCER-05

Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines

Status
forthcoming
Programme
Horizon Europe (HORIZON)
Action type
HORIZON Pre-commercial Procurement
Opens
10 Feb 2027
Deadline
21 Sep 2027
Fetched
15 Jul 2026, 07:18 UTC
Plain-language summary

Pre-commercial procurement for affordable, innovative cancer healthcare solutions across EU countries.

This call supports consortia of public procurers to develop affordable cancer technologies, medical devices, or medicines. Solutions must be clinically validated and piloted in at least five EU or associated countries. End-user involvement and open market consultation are required to ensure relevance and uptake.

Likely relevant for

  • Public healthcare procurers
  • Healthcare technology developers
  • Medical device manufacturers
  • Cancer patient advocacy groups
  • SMEs and startups in health innovation

Project signals

Pre-commercial procurementAffordable cancer healthcare solutionsEnd-user engagementMulti-country clinical validation

What it funds

  • Development of affordable cancer technologies, medical devices, or medicines
  • Pre-commercial procurement by consortia of procurers
  • Clinical validation, piloting, and upscaling in at least five EU/associated countries
  • End-user engagement including patients and healthcare professionals
  • Open market consultation and promotion to suppliers
  • Capacity building and technical assistance for PCP implementation

Expected outcomes

  • Stimulate competitive development of market-ready affordable cancer solutions
  • Solutions address needs of patients living with and beyond cancer
  • Facilitate commercialization with first customer references
  • Exchange and adoption of best practices among stakeholders

Who can apply / participate

  • Consortia of public procurers with similar needs
  • Consortia must include procurers from at least five different EU Member States or Associated Countries
  • At least five different EU Member States or Associated Countries must be involved
  • Direct funding is to procurers, not to developers or industry
  • Procurers must declare intent to purchase solutions resulting from PCP
  • Specific eligibility criteria for non-EU/non-associated countries must be checked

Must check before shortlisting

  • Eligibility of participant types and countries
  • Consortium composition and procurement commitments

Money

Total budget around €26 million for 2027, with expected grants between €8 million and €10 million each for up to 3 projects.

  • Total budget for 2027 — 26000000EUR
    Allocated for this PCP call
  • Expected grants — 8000000-10000000EUR
    Per grant, up to 3 grants expected

Application notes

  • Single-stage submission model.
  • Proposal page limits and layout as per Annex A and E of Horizon Europe Work Programme General Annexes.
  • Eligibility conditions as per Annex B of Horizon Europe Work Programme General Annexes.
  • Financial and operational capacity requirements as per Annex C.
  • Evaluation criteria thresholds: Excellence, Impact, Implementation each minimum 4, cumulative 12.
  • Legal and financial set-up as per Annex G.
  • Use application form available in the Submission System.
  • Organize open market consultation before procurement launch.
  • Declare intent to purchase at least one solution resulting from PCP.
  • Include deliverable preparing follow-up procurement if applicable.
  • This call does not fund developers or industry directly; they respond to tenders launched by procurers.
  • Procurers must ensure end-user involvement and multi-country clinical validation.
  • Check specific eligibility and consortium requirements carefully.

Derived from official EU Funding portal source · updated 7 Jul 2026, 12:23 UTC. Use this as a shortlisting aid; the official call text remains authoritative.

Related calls

These funding calls are closely related and may be worth considering as part of the same funding landscape.

Official source text

Fine print from the EU source record. Expand when you need the original wording.

Topic description

Expected Outcome: This action supports the follow-up to the July 2023 Communication on EU Missions assessment [1] . Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: Public procurers, possibly in cooperation with private ones, in the area of cancer-centred healthcare stimulate the competitive development of market-ready, affordable, innovative solutions. The chosen solutions take into consideration the needs of cancer patients living with and beyond cancer through research that supports end-user engagement using participative research models. Procurers create opportunities for European health, technology and medical devices, industrial actors (including start-ups, spin-offs, spin-outs, scale-ups, SMEs) to bring to the market affordable innovations that are cost-efficient, safe and have demonstrated improved health outcomes for cancer patients living with and beyond cancer. Procurers facilitate the commercialisation of innovative solutions for and with cancer patients by their successful suppliers through providing them with first customer references for the validation and first pilot deployment. Policymakers, healthcare providers and professionals, cancer patients and their carers – each in their respective areas – exchange and adopt good practices and the best treatment, technology and medical device solutions that the market can deliver through participative research. Scope: Pre-commercial procurement (PCP) actions target consortia of procurers with similar needs that want to procure together the development of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines [2] . Proposals should address all of the following: The focus should be on affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines that benefit cancer patients. Within this topic, it is possible to foresee the transfer and adaptation of solutions and/or interventions from other sectors to healthcare systems. It is open both to proposals requiring improvements based on one specific solution or technology, or medical device as well as to proposals requiring end-to-end solutions that need combinations of different types of innovation. The requested innovative solutions for healthcare systems in the areas of affordable cancer technologies, cancer medical devices, or cancer medicines should be clinically validated, piloted or upscaled by the participating procurers in at least five different countries across the EU Member States and Associated Countries. Continuous dialogue between the demand and supply side is required for the success of pre-commercial procurement. Therefore the effective involvement of end-users (e.g. academia, clinical teams, cancer patients and their caregivers/families, cancer patient representatives, local or regional medical services, hospitals, production facilities) must be considered in the proposal. To stimulate dialogue with the supply side, procurers are required to organise an open-market consultation before launching the procurement and to promote the call for tenders widely across Europe to potentially interested suppliers. Procurers should declare in the proposal their interest to purchase at least one solution resulting from the PCP in case the PCP delivers successful solutions and indicate whether they will (1) procure the solution(s) as part of the PCP or (2) in a separate follow-up procurement after the PCP. In the first case, procurers can implement the project as a fast-track PCP (see general annex H) and foresee the budget to purchase at least one solution during the PCP. In the second case, the procurers must include in the proposal a deliverable that prepares the follow-up procurement to purchase successful solution(s) after the PCP. Activities covered should support national healthcare systems and mobilise technical assistance and/or capacity building to other procurers beyond the project to mainstream PCP implementation and to remove obstacles for introducing the innovative solutions for the benefit of cancer patients to be procured into the market. [1] EUR-Lex - 52023DC0457 - EN - EUR-Lex [2] Pre-commercial procurement (PCP) actions target consortia of procurers with similar needs that want to procure together the development of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines. This topic does not provide direct funding to developers, industry or research organisations to perform R&D. They will be able to respond to the call for tenders launched by consortia of procurers funded under this call

Conditions and documents

General conditions

1. Admissibility conditions: Proposal page limit and layout

described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.

2. Eligible countries

described in Annex B of the Work Programme General Annexes.

A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.

3. Other Eligibility Conditions

described in Annex B of the Work Programme General Annexes.

4. Financial and operational capacity and exclusion

described in Annex C of the Work Programme General Annexes.

5a. Evaluation and award: Award criteria, scoring and thresholds

described in Annex D of the Work Programme General Annexes.

5b. Evaluation and award: Submission and evaluation processes

The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.

described in Annex F of the Work Programme General Annexes and the Online Manual.

5c. Evaluation and award: Indicative timeline for evaluation and grant agreement

described in Annex F of the Work Programme General Annexes.

6. Legal and financial set-up of the grants

The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.

described in Annex G of the Work Programme General Annexes.

Specific conditions

described in the specific topic of the Work Programme

Support information

Online Manual is your guide on the procedures from proposal submission to managing your grant. Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe. Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management. Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular. National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’). Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding. IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc. European IPR Helpdesk assists you on intellectual property issues. CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal. The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers. Partner Search help you find a partner organisation for your proposal.

Raw budget overview
{
  "budgetYearsColumns": [
    "2027"
  ],
  "budgetTopicActionMap": {
    "113120": [
      {
        "action": "HORIZON-MISS-2027-02-CANCER-02 - HORIZON-IA HORIZON Innovation Actions",
        "expectedGrants": 3,
        "minContribution": 7000000,
        "maxContribution": 10000000,
        "budgetYearMap": {
          "2027": "20000000"
        },
        "plannedOpeningDate": "2027-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2027-09-21"
        ]
      }
    ],
    "113121": [
      {
        "action": "HORIZON-MISS-2027-02-CANCER-03 - HORIZON-RIA HORIZON  Research and Innovation Actions",
        "expectedGrants": 3,
        "minContribution": 7000000,
        "maxContribution": 9000000,
        "budgetYearMap": {
          "2027": "24000000"
        },
        "plannedOpeningDate": "2027-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2027-09-21"
        ]
      }
    ],
    "113122": [
      {
        "action": "HORIZON-MISS-2027-02-CANCER-01 - HORIZON-RIA HORIZON  Research and Innovation Actions",
        "expectedGrants": 4,
        "minContribution": 7000000,
        "maxContribution": 8000000,
        "budgetYearMap": {
          "2027": "32323812"
        },
        "plannedOpeningDate": "2027-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2027-09-21"
        ]
      }
    ],
    "113123": [
      {
        "action": "HORIZON-MISS-2027-02-CANCER-06 - HORIZON-CSA HORIZON Coordination and Support Actions",
        "expectedGrants": 1,
        "minContribution": 3000000,
        "maxContribution": 3000000,
        "budgetYearMap": {
          "2027": "3000000"
        },
        "plannedOpeningDate": "2027-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2027-09-21"
        ]
      }
    ],
    "113124": [
      {
        "action": "HORIZON-MISS-2027-02-CANCER-04 - HORIZON-RIA HORIZON  Research and Innovation Actions",
        "expectedGrants": 3,
        "minContribution": 5000000,
        "maxContribution": 7000000,
        "budgetYearMap": {
          "2027": "10000000"
        },
        "plannedOpeningDate": "2027-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2027-09-21"
        ]
      }
    ],
    "113125": [
      {
        "action": "HORIZON-MISS-2027-02-CANCER-05 - HORIZON-PCP HORIZON Pre-commercial Procurement",
        "expectedGrants": 3,
        "minContribution": 8000000,
        "maxContribution": 10000000,
        "budgetYearMap": {
          "2027": "26000000"
        },
        "plannedOpeningDate": "2027-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2027-09-21"
        ]
      }
    ]
  }
}